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ABSTRACT: GIRK channels are activated by a large number of
G protein-coupled receptors and regulate the electrical activity of
neurons, cardiac atrial myocytes, and β-pancreatic cells.
Abnormalities in GIRK channel function have been implicated
in the pathophysiology of neuropathic pain, drug addiction, and
cardiac arrhythmias. In the heart, GIRK channels are selectively
expressed in the atrium, and their activation inhibits pacemaker
activity, thereby slowing the heart rate. In the present study, 19
new diterpenes, falcatins A−S (1−19), and the known
euphorprolitherin D (20) were isolated from Euphorbia falcata.
The compounds were assayed on stable transfected HEK-hERG
(Kv11.1) and HEK-GIRK1/4 (Kir3.1 and Kir3.4) cells. Blocking
activity on GIRK channels was exerted by 13 compounds (61−
83% at 10 μM), and, among them, five possessed low potency on
the hERG channel (4−20% at 10 μM). These selective activities suggest that myrsinane-related diterpenes are potential lead
compounds for the treatment of atrial fibrillation.
Cardiovascular diseases are the leading cause of death andloss of disability-adjusted life-years worldwide.1 A notable
portion of such diseases are linked to the dysfunction of cardiac
ion channels. Ion channels are a large and diverse family of
transmembrane pore-forming proteins.2−8 These proteins
facilitate the rapid passive transport of specific inorganic ions
(such as Na+, K+, Ca2+, and Cl−) through the lipid bilayers of
plasma and organelle membranes down their electrochemical
gradient that is established by the work of pumps and
transporters.2,6−10 Defined by the stimulus necessary to evoke
activity, the majority of ion channels are classified commonly into
two main subgroups: voltage-gated and ligand-gated channels.
The most important difference is that voltage-gated ion channels
are activated by changes in plasma membrane potential, while
ligand-gated channels are activated by endogenous ligands.4−11
Ion channels are also grouped into various subclasses by another
key functional characteristic, their selective permeability to
different ions.8,9,12 Voltage-gated ion channels are rather specific
for the various cations and anions. Therefore, these channels are
typically named after the ion for which they are selective. Several
classes of potassium channels play an important role in the
regulation of function of the myocardium.
GIRK channels (G protein-activated inwardly rectifying
potassium ion channels) are involved in the regulation of the
electrical activity of neurons, cardiac atrial myocytes, and β-
pancreatic cells. Abnormalities in GIRK channel function have
been implicated in the pathophysiology of neuropathic pain, drug
addiction, cardiac arrhythmias, and other disorders.13 In the heart
muscles, GIRK potassium channels are selectively expressed in
the cardiac atrium, activated by a large number of G protein-
coupled receptors and responsible for K+-fluxes and membrane
repolarization and/or hyperpolarization. Electrical remodeling of
atrial heart muscle during chronic atrial fibrillation may result in a
constitutively active form of the GIRK channel, which may lead
to an important role of this channel in this disease. Selective
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inhibition of myocardial GIRK channels in animal atrial
fibrillation models reduces the number of provoked atrial
fibrillation episodes and decreases the duration of these
arrhythmic periods. Therefore, selective blockade of the GIRK
channel might be a useful tool in the treatment of atrial
fibrillation, and these channels are novel targets in the search for
new antiarrhythmic agents.14−16
hERG channels (human ether-a-go-go-related gene encoded
potassium channels) are K+-selective voltage-gated ion channels,
belonging to the Kv channel family, also referred to as Kv11.1.
hERG channels mediate the rapid delayed rectifier K+ current
(IKr) in ventricular myocytes and are expressed in both the atrium
and ventricle. These channels can be blocked by chemicals with
diverse structures that encompass several therapeutic drug
classes, including antiarrhythmics, psychiatric agents, antimicro-
bials, and antihistamines.17 Compounds with hERG-blocking
activity may modify the action potential of the heart muscle,
which can lead to prolongation of the action potential and an
increased risk of severe ventricular arrhythmias such as
ventricular fibrillation and sudden cardiac death. hERG-blocking
activity has been the reason for the withdrawal of several would-
be “blockbuster” drugs from the market. At present, every new
drugmust go through preclinical safety testing determined by the
U.S. Food and Drug Administration, the European Medicines
Agency, and other regulatory entities.2,3,5,8,18−20
For many years natural products have made a major impact in
the treatment of cardiovascular diseases. More recently, a
number of bioactive compounds generally obtained from
terrestrial plants such as carotenoids, catechin, isoflavones,
quercetin, resveratrol, sulforaphane, and tocotrienols have been
proven to promote cardioprotection and to reduce the risk of
cardiovascular diseases.21 Great efforts are ongoing worldwide in
the search for new natural compounds that can selectively
influence these diseases.
Plants in the genus Euphorbia are well known for the chemical
diversity of their diterpenoids. Several of them are of particular
interest because of their restricted occurrence and broad
structural diversity, as a consequence of different frameworks
such as jatrophanes, tiglianes, ingenanes, lathyranes, myrsinanes,
and daphnanes.22 Previous studies have indicated that diterpenes
of Euphorbia species have a wide variety of biological activities,
such as skin-irritant, antiproliferative, cytotoxic, and antiviral
properties and multidrug resistance modulating and anti-
inflammatory effects.22−24 However, no data have been reported
concerning the potential cardiac effects of this type of natural
compound.
As a part of our research program to discover new bioactive
compounds from Euphorbia species, the chloroform-soluble
fraction of a methanol extract of Euphorbia falcata L.
(Euphorbiaceae) was investigated. This study resulted in the
isolation and structure determination from this plant of 19 new
diterpenes (falcatins A−S, 1−19) and one known diterpene
(euphorprolitherin D, 20) based on myrsinane, premyrsinane,
and cyclomyrsinane skeletons. These compounds together with
four premyrsinane and cyclomyrsinane-type diterpenes (21−
24),25,26 isolated earlier from this plant by our group, were
studied for their GIRK- and hERG channel-inhibitory activities
using an automated patch-clamp method.
■ RESULTS AND DISCUSSION
Twenty diterpenes (1−20) were isolated from the CHCl3-
soluble phase of the MeOH extract prepared from the whole
plant of E. falcata by a combination of different chromatographic
methods, such as CC, VLC, CPC, preparative TLC, and HPLC.
The structure elucidation was carried out by spectroscopic
analysis, including 1D and 2D NMR (1H−1H COSY, HSQC,
HMBC, and NOESY) and HRESIMS experiments. The NMR
data showed that all compounds are myrsinane-related
diterpenes (myrsinanes, premyrsinanes, and cyclomyrsinanes).
Characterization of Compounds 1−19.Compound 1was
obtained as an amorphous solid with [α]25D −8 (c 0.2, CHCl3).
Its HRESIMS provided the molecular formula, C35H42O12,
through the presence of a peak at m/z 677.2594 [M + Na]+
(calcd for C35H42O12Na, 677.2574). The
1H and 13C NMR
spectra of 1 revealed the presence of four acetyl groups [δH 1.97 s,
2.01 s, 2.06, and 2.16 s; δC 170.5, 169.2, 170.1, and 168.3 (CO)
and 22.4, 21.1, 21.0, and 23.2 (CH3)] and one benzoyl
substituent [δH 7.94 d, 7.40 and 7.53 t; δC 166.8, 129.3, 128.0,
132.6, and 131.0] (Tables 1 and 2). Additionally, the 1H NMR
spectrum exhibited signals attributed to skeletal protons,
including four methyls (0.88 d, 1.59 s, 1.45 s, and 1.24 s). The
1H−1H COSY spectrum defined two structural fragments with
correlated protons:−CH2−CH(CH3)−CHR−CH−CHR− (A)
(δH 2.83, 2.61, 2.27, 5.63, 3.15, and 6.00) and −CHCH− (B)
(δH 6.19 and 6.54). These two structural parts and the tertiary
methyls and quaternary carbons were connected by inspection of
the long-range C−H correlations observed in the HMBC
spectrum (Figure 1). The two- and three-bond correlations
between the quaternary carbon C-15 and H-1, H-3, and H-4 and
between C-4 and H-1 and H-5 revealed that structural fragment
A together with C-15 forms a five-membered ring, present in
many types of Euphorbiaceae diterpenes. HMBC cross-peaks
Figure 1. Selected 1H−1H COSY (bold) and HMBC (C→H)
correlations for 1.
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between C-6 and H-4, H-8, and H-12, between C-7 and H-8, and
between C-10 and H-12, H-18, and H-19 established a 10,18-
dihydromyrsinol-type diterpene with O-functionalities at C-3, C-
5, C-7, C-10, C-14, and C-15. Moreover, the heteronuclear long-
range coupling between C-5 and H-17 and H-12, C-6 and H-17
and H-12, and between C-13 and H-17 indicated an O-bridge
between C-17 and C-13, which is characteristic of many
myrsinane, cyclomyrsinane, and premyrsinane polyesters. The
positions of the ester groups were established via the HMBC
experiment. The correlations of the carbonyl signal at δC 169.2
with the proton signal at δH 6.00 (H-5) and the acetyl methyl
signal at δH 2.01, and the carbonyl signal at δC 170.1 with the
proton signal at δH 5.13 (H-14) and the acetyl methyl signal at δH
2.06, indicated the presence of two acetyl groups at C-5 and C-
14. Similarly, the HMBC cross-peak of the signal at δC 166.8
(benzoyl CO) with the proton signals at δH 5.63 (H-3)
demonstrated the presence of the benzoyl group at C-3. The
acetyl group at C-15 was indicated by the weak four-bond
HMBC correlation between C-15 and the acetyl methyl signal at
δH 2.16. Furthermore, the position of the OAc-15 group was
corroborated by the NOESY correlations between Bz-2′,6′ and
OAc-15.
The relative configuration of 1 was elucidated as follows. For
the reported natural myrsinol diterpenes, the three rings (5/7/6)
forming the myrsinol skeleton are trans-fused, H-4 and H2-17 are
α-oriented, and Me-16, H-12, the side chain at C-11, and the C-
15 acetyl group are β-oriented (Figure 2).27 NOESY correlations
of 1 observed for H-2/H-3, H-3/H-4, H-4/H-14, H-4/H-2, and
H-14/H-1b suggested that H-1b, H-2, H-3, H-4, and H-14 are α-
oriented, while correlations between H-1a/H3-16 and H-5/H-12
proved the β-orientation of H-1a and H-5.
This stereochemistry of 1 was in agreement with the
configuration of 10,18-dihydromyrsinol diterpenes reported
earlier.28,29 All of the above evidence confirmed the structure
of 1 as 5α,10,14β,15β-O-tetraacetyl-3β-O-benzoyl-10,18-dihy-
dromyrsinol, which was named falcatin A.
Compound 2 was obtained as an amorphous solid with [α]28D
+22 (c 0.1, CHCl3). It was found to possess a molecular formula
Table 1. 1H NMR Data (δH) of Compounds 1−6 [δ ppm (J = Hz), CDCl3, 500 MHz]
position 1 2 3 4 5 6
1α 2.83, dd (15.8, 10.9) 2.80, dd (15.8, 9.8) 2.76, dd (15.8, 10.9) 3.06, dd (14.5, 9.0) 3.14, dd (14.4, 5.6) 2.92, m
1β 2.61, dd (15.8, 9.1) 2.50, dd (15.8, 9.3) 2.54, m 1.75, dd (14.5, 9.2) 1.76, dd (14.4, 10.1) 1.75, dd (14.5, 9.3)
2 2.27, m 2.18, m 2.16, m 2.13, m 2.15, m 2.09, m
3 5.63, t (3.8) 5.41, t (3.4) 5.39, t (3.5, 3.2) 5.51, t (4.4) 5.53, t (4.1) 5.55, t (3.8)
4 3.15, dd (10.9, 3.7) 3.00, dd (10.8, 3.4) 3.01, dd (10.9, 3.6) 2.91, m 2.84, dd (11.0, 4.2) 3.04, dd (11.1, 3.8)
5 6.00, d (10.9) 5.92, d (10.8) 5.90, d (10.9) 6.50, d (11.3) 6.49, d (11.1) 6.48, d (11.1)
7 5.16, d (5.3) 5.21, d (5.3) 5.07, d (5.3)
8 6.19, d (10.3) 6.22, d (10.3) 6.20, d (10.2) 6.01, m 6.04, m 6.02, m
9 6.54, dd (10.3, 6.2) 6.57, dd (10.3, 6.4) 6.55, dd (10.2, 6.3) 5.87, dd (9.8, 1.9) 5.87, d (9.8) 5.84, d (9.8)
11 3,07, brm 3.06, brm 3.03, brm 2.91, m 2.88, d (12.8) 2.92, m
12 3.58, s 3.54, s 3.53, s 3.45, d (12.7) 3.42, d (12.8) 3.20, d (12.7)
14 5.13, s 5.08, s 5.06, s
16 0.88, d (6.8) 0.84, d (6.8) 0.82, d (6.8) 0.92, d (6.9) 0.88, d (7.0) 0.90, d (6.8)
17 4.31, d (9.1) 4.28, d (9.0) 4.26, d (9.1) 4.48, d (12.1) 4.59, d (12.1) 4.50, d (12.0)
3.87, d (9.1) 3.87, d (9.0) 3.84, d (9.1) 4.29, d (12.1) 4.12, d (12.1) 4.32, d (12.0)
18 1.59, s 1.59, s 1.57, s 1.04, s 1.03, s 1.06, s
19 1.45, s 1.46, s 1.45, s 1.44, s 1.43, s 1.45, s
20 1.24, s 1.23, s 1.22, s 1.57, s 1.60, s 1.54, s
OiBu-3
2 2.58, sept (7.0) 2.43, m 2.47, sept (7.0)
3 1.18, d (7.0) 1.13, d (7.1) 1.14, d (7.1)
4 1.18, d (7.0) 0.93, d (7.0) 0.99, d (6.9)
OProp-3
2 2.43, dq, 2.31, dq (16.6, 7.8) 2.22, m (2H)
3 1.16, t (7.8) 0.94, t (7.2)
OAc-5 2.01, s 2.03, s 2.01, s 2.24, s
OAc-7 2.24, s 2.17, s
OAc-10 1.97, s 2.02, s 2.00, s
OAc-14 2.06, s 2.06, s 2.04, s
OAc-15 2.16, s 2.10, s 2.09, s 2.22, s 2.22, s
OAc-17 1.54, s
OiBu-17
2 2.09, sept (6.8) 2.20, m
3 0.96, d (6.8) 0.99, d (6.9)
4 0.93, d (6.9) 0.95, d (6.9)
OBz
2, 6 7.94, d (7.0) 7.88, d (7.1) 7.89, d (7.3) 7.88, d (7.4)
3, 5 7.40, t (7.8) 7.39, t (7.8) 7.54, t (7.4) 7.39, t (7.6)
4 7.53, t (7.5) 7.53, t (7.5) 7.40, t (7.7) 7.53, t (7.3)
OH-15 2.83, s
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of C31H42O12 based on the HRESIMS [m/z 629.2600 [M +Na]
+
(calcd for C31H42O12Na, 629.2574)]. The
1H NMR and JMOD
spectra of 2 revealed four acetate [δH 2.02 s, 2.03 s, 2.06 and 2.10
s; δC 170.4, 169.4, 170.1, and 168.3 (CO) and 22.5, 21.2, 21.0,
and 23.0 (CH3)] and one propanoate [δH 2.43 dq, 2.31 dq and
1.16 t; δC 174.8, 27.7, and 9.0] group (Tables 1 and 2).
Additionally, the spectra exhibited resonances closely related to
those of 1.
After the 1H and 13C NMR data on 2 had been assigned by
analysis of its 1H−1H COSY, HSQC, and HMBC spectra, it was
obvious that compounds 1 and 2 are based on the same parent
system and differ only in the substitution on C-3. The absence of
Table 2. 13C NMR Data (δC) of Compounds 1−6 (CDCl3, 125 MHz)
position 1 2 3 4 5 6
1 44.3, CH2 43.8, CH2 44.0, CH2 42.8, CH2 n.d.
a 46.3, CH2
2 36.5, CH 35.9, CH 36.1, CH 36.0, CH n.d.a 36.0, CH
3 76.7, CH 76.0, CH 75.8, CH 77.2, CH 77.0, CH 78.4, CH
4 52.4, CH 52.4, CH 52.2, CH 50.9, CH 51.4, CH 50.1, CH
5 66.8, CH 67.0, CH 66.8, CH 68.8, CH 69.1, CH 69.0, CH
6 61.8, C 61.7, C 61.7, C 47.0, C n.d.a 47.1, C
7 197.3, C 197.3, C 197.3, C 68.2, CH 68.0, CH 68.3, CH
8 131.6, CH 131.7, CH 131.6, CH 126.1, CH 126.3, CH 126.3, CH
9 140.7, CH 140.8, CH 140.7, CH 129.0, CH 128.9, CH 128.9, CH
10 85.4, C 85.5, C 85.3, C 79.3, C 80.8, C 79.2, C
11 42.5, CH n.d.a n.d.a 47.4, CH 47.7, CH 47.6, CH
12 41.7, CH 41.5, CH 41.5, CH 41.8, CH 42.1, CH 41.7, CH
13 89.3, C 89.2, C 89.3, C 84.6, C 85.5, C 85.3, C
14 81.1, CH 81.0, CH 81.0, CH 200.2, C 201.5, C 205.3, C
15 90.4, C 90.5, C 90.3, C 88.9, C 90.4, C 83.6, C
16 14.2, CH3 14.2, CH3 14.0, CH3 14.3, CH3 14.5, CH3 14.5, CH3
17 72.2, CH2 72.2, CH2 72.1, CH2 61.4, CH2 61.3, CH2 61.6, CH2
18 23.6, CH3 23.8, CH3 23.7, CH3 24.8, CH3 25.0, CH3 24.6, CH3
19 24.0, CH3 24.0, CH3 23.9, CH3 29.7, CH3 29.4, CH3 29.5, CH3
20 23.6, CH3 23.0, CH3 23.5, CH3 26.1, CH3 26.0, CH3 24.7, CH3
OiBu-3 1 176.6, C 175.2, C
2 34.3, CH 34.1, CH
3 19.3, CH3 19.3, CH3
4 19.3, CH3 19.0, CH3
OAc-5 169.2, C 169.4, C 169.4, C
21.1, CH3 21.2, CH3 21.2, CH3
OAc-7 170.0, C 171.4, C 170.0, C
21.2, CH3 21.5, CH3 21.2, CH3
OAc-10 170.5, C 170.4, C 170.4, C
22.4, CH3 22.5, CH3 22.4, CH3
OAc-14 170.1, C 170.1, C 170.1, C
21.0, CH3 21.0, CH3 21.0, CH3
OAc-15 168.3, C 168.3, C 168.3, C 168.0, C 170.1, C
23.2, CH3 23.0, CH3 22.9, CH3 21.4, CH3 20.6, CH3
OAc-17 171.9, C
21.5, CH3
OBz CO 166.8, C 165.5, C 166.6, C 165.0, C
1 131.0, C 129.7, C 130.7, C 129.7, C
2, 6 129.3, CH 129.6, CH 129.8, CH 129.6, CH
3, 5 128.0, CH 128.3, CH 128.5, CH 128.3, CH
4 132.6, CH 133.3, CH 133.3, CH 133.2, CH
OiBu-3 1 177.2, C
2 35.6, CH
3 20.7, CH3
4 19.5, CH3
OiBu-17 1 176.5, C 176.5, C
2 33.9, CH 33.8, CH
3 19.0, CH3 19.0, CH3
4 18.2, CH3 17.6, CH3
OProp-3 1 174.8, C 173.1, C
2 27.7, CH2 27.4, CH2
3 9.0, CH3 8.7, CH3
an.d., not detected.
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signals for a benzoate group and the appearance of signals of a
propanoate group indicated the replacement of a benzoate
residue with a propanoate group. The position of the propanoyl
group at C-3 was corroborated by the HMBC cross-peak
between δH 5.41 (H-3) and the carbon signal at δC 174.8
(propanoyl CO). In the case of the acetyl groups, weak 4JC,H
couplings were also detected in the HMBC spectrum between C-
5, C-10, and C-14 and the corresponding acetate methyl protons,
proving unequivocally the locations of acetate groups.
Figure 2. Diagnostic NOESY correlations of 1.
Table 3. 1H NMR Data (δH) of Compounds 7−12 (CDCl3, 500 MHza or 600 MHzb)
position 7b 8a 9a 10a 11a 12a
1α 2.89, dd (15.5, 11.5) 2.55, m 2.93, dd (15.9, 11.0) 3.69, d (16.3) 3.67, d (16.3) 2.84, d (16.7)
1β 2.29, m 2.78, m 2.66, m 1.97, d (16.3) 2.00, d (16.2) 3.83, d (16.8)
2 2.22, m 2.20, m 2.33, m
3 5.68, t (3.0) 5.44, t (3.9) 5.73, t (3.7) 5.02, d (6.2) 5.02, d (6.2) 5.61, d (4.3)
4 3.16, dd (11.0, 3.0) 2.97, dd (11.0, 3.9) 3.10, dd (10.6, 3.6) 2.94, dd (10.5, 6.2) 2.98, dd (10.8, 6.2) 3.20, dd (10.9, 4.4)
5 6.13, d (11.0) 5.90, d (11.0) 5.86, d (10.6) 5.93, d (10.5) 5.93, d (10.8) 5.91, d (10.7)
8 5.00, d (7.2) 5.25, d (6.9) 5.21, d (7.0) 5.29, d (6.6) 5.29, d (6.7) 5.27, d (6.9)
9 2.81, m 2.75, m 2.73, m 2.75, m 2.70, m 2.75, m
11 2.36, m 2.41, dt (12.5, 2.0) 2.40, m 2.45, m 2.50, dd (10.5, 7.4) 2.48, m
12 3.99, d (12.6) 4.09, d (12.5) 4.10, d (12.3) 3.96, d (12.2) 3.96, d (12.3) 4.01, d (12.3)
14 5.05, s 5.04, s 5.12, s 4.94, s 4.95, s 5.05, s
16 0.87, d (6.6) 0.86, d (6.8) 0.94, d (6.7) 1.46, s 1.46, s 1.79, s
17 4.29, d (9.6) 4.21, d (9.8) 4.26, d (9.8) 4.24, d (9.8) 4.24, d (9.8) 4.27, d (9.9)
3.61, d (9.6) 3.60, d (9.8) 3.61, d (9.8) 3.59, d (9.8) 3.60, d (9.8) 3.62, d (9.9)
18 1.57, s 1.64, s 1.64, s 1.66, s 1.64, s 1.65, s
19 2.58, m 2.53, m 2.50, m 2.52, d (9.2) 2.52, m 2.52, d (9.1)
20 1.14, s 1.20, s 1.22, s 1.18, s 1.26, s 1.20, s
OiBu-3
2 2.46, sept (7.1) 2.51, sept (7.0) 2.42, m
3 1.17, d (7.1) 1.18, d (7.1) 1.06, d (6.9)
4 1.14, d (6.9) 1.10, d (6.9) 1.00, d (7.2)
OProp-3
2 2.28, q (7.6)
3 1.10, t (7.6)
OAc-3 2.01, s
OAc-5 1.92, s 1.95, s 1.90, s 1.89, s 1.96, s
OAc-8 2.27, s
OAc-10 1.92, s 2.10, s 2.11, sc 2.09, s 2.09, s 2.08, s
OAc-14 2.02, s 2.10, s 2.13, s 2.09, s 2.09, s 2.11, s
OAc-15 1.53, s 2.20, s 2.30, sc 2.18, s 2.19, s 2.16, s
OBz-5
2, 6 7.88, d (6.6)
3, 5 6.46, t (7.8)
4 7.12, t (7.8)
OMeBu-8
2 2.20, m 2.67, m 2.65, m 2.62 m
3 1.55, m; 1.40, m 1.75, m; 1.60, m 1.75, m; 1.58, m 1.63, m; 1.72, m
4 0.78, t (7.4) 0.92, t (7.5) 0.92, t (7.5) 0.87, t (7.4)
5 0.60, d (6.8) 1.31, d (6.9) 1.32, d (6.9) 1.25, d (6.9)
ONic
2 9.10, s 9.06, s
4 8.29, d (8.0) 8.14, d (8.0)
5 7.40, dd (7.8, 4.8) 7.35, dd (7.8, 4.9)
6 8.78, d (4.8) 8.75, d (4.9)
OBz-8
2, 6 7.88, d (6.6)
3, 5 7.43, t (7.2)
4 7.62, t (7.2)
cData are interchangeable.
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Table 4. 13C NMR Data (δC) of Compounds 7−12 (CDCl3, 125 MHza or 150 MHzb)
position 7b 8a 9a 10a 11a 12a
1 43.2, CH2 43.1, CH2 43.3, CH2 51.0, CH2 51.0, CH2 48.3, CH2
2 37.2, CH 36.3, CH 36.4, CH 75.3, C 75.5, C 85.0, C
3 78.0, CH 76.7, CH 78.4, CH 80.1, CH 80.0, CH 78.2, CH
4 51.4, CH 51.0, CH 51.5, CH 49.6, CH 49.4, CH 47.2, CH
5 68.3, CH 68.9, CH 68.5, CH 69.5, CH 69.5, CH 68.4, CH
6 62.3, C 62.2, C 62.1, C 62.3, C 62.3, C 62.5, C
7 204.3, C 204.4, C 204.4, C 204.7, C 204.7, C 204.2, C
8 74.3, CH 71.4, CH 70.8, CH 71.3, CH 71.3, CH 71.2, CH
9 30.7, CH 29.8, CH 30.0, CH 30.1, CH 30.1, CH 30.1, CH
10 77.8, C 77.5, C 77.5, C 77.5, C 77.6, C 77.6, C
11 42.0, CH 41.8, CH 41.9, CH 41.5, CH 41.6, CH 41.8, CH
12 41.1, CH 41.4, CH 41.3, CH 41.3, CH 41.3, CH 41.5, CH
13 89.6, C 89.3, C 89.4, C 88.6, C 88.7, C 89.3, C
14 81.9, CH 81.9, CH 82.0, CH 80.8, CH 81.0, CH 81.9, CH
15 89.9, C 90.3, C 90.5, C 89.9, C 89.9, C 88.6, C
16 13.9, CH3 13.9, CH3 14.1, CH3 29.7, CH3 29.7, CH3 25.0, CH3
17 67.4, CH2 67.1, CH2 67.1, CH2 66.9, CH2 67.0, CH2 67.3, CH2
18 24.0, CH3 24.4, CH3 24.4, CH3 24.6, CH3 24.6, CH3 24.6, CH3
19 37.1, CH2 35.0, CH2 34.9, CH2 35.0, CH2 35.0, CH2 35.3, CH2
20 21.7, CH3 22.2, CH3 22.3, CH3 22.0, CH3 22.3, CH3 22.4, CH3
OAc-3 169.9, C
21.0, CH3
OAc-5 170.0, C 169.2, C 169.5, C 169.5, C 169.7, C
20.7, CH3 20.8, CH3 20.7, CH3 20.6, CH3 20.9, CH3
OAc-8 168.5, C
21.3, CH3
OAc-10 168.9, C 169.0, C 169.2, C 168.7, C 168.7, C 168.8, C
21.7, CH3 21.3, CH3 21.3, CH3 21.3, CH3 21.3, CH3 21.3, CH3
OAc-14 170.7, C 170.6, C 170.6, C 170.2, C 170.2, C 170.3, C
21.3, CH3 21.7, CH3 21.7, CH3 21.3, CH3 21.6, CH3 21.7, CH3
OAc-15 167.5, C 167.9, C 168.1, C 169.2, C 169.1, C 168.2, C
22.6 CH3 23.5, CH3 23.4, CH3 23.2, CH3 23.2, CH3 23.2, CH3
OProp-3 1 174.3, C
2 27.1, CH2
3 8.9, CH3
OiBu-3 1 176.0, C 177.1, C 175.3, C
2 34.3, CH 33.9, CH 34.1, CH
3 18.6, CH3 19.6, CH3 18.4, CH3
4 19.4, CH3 18.2, CH3 19.0, CH3
OBz-5 CO 166.0, C
1 129.5, C
2, 6 129.6, CH
3, 5 128.1, CH
4 132.8, CH
OMeBu-8 1 174.6, C 174.5, C 174.6, C 174.6, C
2 40.9, CH 41.0, CH 41.0, CH 41.1, CH
3 26.9, CH2 27.0, CH2 27.0, CH2 27.0, CH2
4 11.0, CH3 11.0, CH3 11.0, CH3 11.0, CH3
5 15.0, CH3 15.9, CH3 15.7, CH3 15.9, CH3
OBz-8 CO 166.5, C
1 130.6, C
2,6 129.8, CH
3,5 128.9, CH
4 133.0, CH
ONic CO 164.5, C n.d.c
2 150.1, CH 150.9, CH
3 126.2, CH 128.0, CH
4 137.1, CH 137.5, CH
5 123.5, CH 123.8, CH
6 153.5, CH 153.5, CH
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Evaluation of the NOESY spectrum of 2 led to the conclusion
that its configuration is the same as that of 1. Diagnostic nuclear
Overhauser effects were detected between H-4/H-3, H-4/H-1b,
H-4/H-2, H-4/H-14, H-4/H-17a, H-3/OAc-5, and H-11/H-18,
which proved the α-orientation of these protons. Moreover, the
cross-peaks between H-5/H-12 and H-12/H-20 supported the
β-orientation of H-5, H-12, and H-20. The structure of falcatin B
(2) was elucidated therefore as 5α,10,14β,15β-O-tetraacetyl-3β-
O-propanoyl-10,18-dihydromyrsinol.
Compound 3 was isolated as a colorless, amorphous solid with
[α]28D +13 (c 0.1, CHCl3). Its HRESIMS displayed a
pseudomolecular ion peak at m/z 643.2756 [M + Na]+,
indicating a molecular composition of C32H44O12. The
1H
NMR and JMOD spectra of 3 revealed four acetate and one
isobutanoate group (Tables 1 and 2). Additionally, the spectra
exhibited resonances closely related to those of 1 and 2. 1H and
13CNMR assignments of 3, determined by analysis of the 1H−1H
COSY, HSQC, and HMBC spectra, clearly showed that
compounds 1−3 are based on the same parent system and differ
only in the substitution at C-3. In the case of 3, an isobutanoate
group can be found in this position, and its location was
corroborated by the HMBC cross-peak between δH 5.39 (H-3)
and the carbon signal at δC 176.6 (isobutanoyl CO). Comparison
of the NOESY spectra of 2 and 3 indicated the same
configuration for 3 and 2. Therefore, falcatin C (3) was
elucidated as 5α,10,14β,15β-O-tetraacetyl-3β-O-isobutyryl-
10,18-dihydromyrsinol.
Compound 4 was obtained as an amorphous solid with [α]25D
+16 (c 0.1, CHCl3). It gave the molecular formula C38H48O12, as
determined from the HRESIMS by the protonated molecular ion
peak at m/z 697.3256 [M + H]+ (calcd for C38H49O12,
697.3224). Apart from the signals for the benzoyl group, the
main difference between 4 and 3 was the transposition of the
locations of the keto group (at C-7 in 3 and C-14 in 4) and an
ester group (at C-14 in 3 and C-7 in 4) (Tables 1 and 2). In
addition, the chemical shift values of C-10 (δC 79.3) and C-13
(δC 84.6) suggested a rearranged tetrahydrofuran ring in the
structure due to the ether bridge between C-10 and C-13 in
4.30−32 In compound 4, the OH-17 group was esterified with an
isobutanoic acid, as indicated by the HMBC cross-peaks between
the carbon signal at δC 176.5 (iBu CO) and H-17. The locations
of the acyl groups at C-3, C-5, and C-7 were determined by the
HMBC correlations of H-3, H-5, and H-7 to the corresponding
carbonyl carbons of the acyl groups. The remaining acetoxy
group was attached of necessity at C-15. The myrsinol-type
diterpene skeleton of 4 implied the same trans-fusion of the three
rings as those of compounds 1−3. The NOESY correlations of
H-2/H-3, H-3/H-4, and H-4/H2-17 suggested that H-3, H-4,
and H-17 are α-oriented. Correlations of H-5/H-12 and H-12/
H3-18 proved the β-orientation of H-5, H-12, and H3-18, while
NOEs between H-19/H-11 and H-20/H-17/H-1a/H-4 con-
firmed the α-orientation of these protons. Thus, compound 4
(falcatin D) was elucidated as 7β,15β-O-diacetyl-5α-O-benzoyl-
17α-O-isobutanoyl-3β-O-propanoyl-10,13-epoxy-10,18-dihy-
dromyrsinol.
The molecular formula for compound 5 was determined as
C37H46O12 on the basis of the HRESIMS [m/z 683.3092 [M +
H]+ (calcd for C37H47O12, 683.3068)]. Comparing the chemical
shifts for the skeletal carbons in 5 with those of compound 4, the
close similarity implied that compounds 4 and 5 possess the same
10,13-epoxy-10,18-dihydromyrsinol framework (Tables 1 and
2). Following the sameNMRprocedures used for 4, the locations
of the acyloxy groups in 5 and the configuration of the compound
were determined by analysis of the HMBC and NOESY spectra.
HMBC cross-peaks revealed acetoxy groups at C-7, C-15, and C-
17, the isobutyryloxy group at C-3, and the benzoyloxy group at
C-5, respectively. NOESY correlations of H-2/H-3, H-3/H-4, H-
4/H2-17, H2-17/H-7, H-5/H-12, H-12/H3-18, H-11/H3-19, and
H2-17/H3-20 allowed the stereochemical features to be assigned,
which were identical with those of compound 4. The structure of
falcatin E was elucidated therefore as 7β,15β,17α-O-triacetyl-5α-
O-benzoyl-3β-O-isobutyryl-10,13-epoxy-10,18-dihydromyrsi-
nol.
Compound 6 was obtained as an amorphous solid with [α]25D
+2 (c 0.1, CHCl3). It exhibited a molecular formula of C37H48O11
based on the HRESIMS [m/z 691.3125 [M + Na]+ (calcd for
C37H48O11Na, 691.3094)]. The
1H and 13C NMR spectra of
compound 6 were similar to those of 4 and 5 (Tables 1 and 2).
For compound 6, one acetoxy group, two isobutyryloxy units,
and one benzoyloxy group were evident from its 1D NMR
spectra (Table 1). The position of the acyloxy groups and the
configuration of 6 were determined using HMBC and NOESY
experiments. Nuclear Overhauser effects indicated that H-2, H-3,
H-4, H-7, H2-17, and H3-20 are α-oriented and H-5, H-12, and
the epoxy bridge are β-oriented. The differences between 6 and 5
were the presence of an isobutyroyl group at C-17 and a hydroxy
group at C-15 instead of two acetyl groups at these positions.
Therefore, compound 6 (falcatin F) was elucidated as 7β-O-
acetyl-5α-O-benzoyl-15β-hydroxy-3β,17-O-diisobutyryl-10,13-
epoxy-10,18-dihydromyrsinol.
The molecular formula C40H44O13 of falcatin G (7) was
assigned according to the HRESIMS at m/z 775.2986 [M + H]+
(calcd for C42H47O14, 775.2966). From the
1H and 13C NMR
spectra, three acetoxy and two benzoyloxy groups were evident
(Tables 3 and 4). The remaining 20 resonances in the 13C NMR
spectrum suggested a cyclomyrsinol-type diterpene skeleton for
7. The characteristic cyclobutane ring, which is built with
incorporation of one of the geminal dimethyl groups (C-19)
besides C-9, C-10, and C-11 of the myrsinane skeleton, can be
characterized by two methines [δC 29.8−30.7 (C-9), 41.1−41.5
(C-11)], one methylene [δC 34.6−37.1 (C-19)], and one O-
substituted quaternary carbon [δC 77.5−77.8 (C-10)], due to the
connection of an ester and a methyl group (C-18) in this
position.25,28,29
The substitution pattern of compound 7was determined using
HMBC andNOESY experiments. The HMBC correlations of H-
3, H-5, H-8, and H-14 to the corresponding carbonyl carbons
revealed that the two acetoxy and two benzoyloxy groups are
attached at C-3, C-5 and C-8, C-14, respectively. The remaining
acetoxy groups were placed at C-10 and C-15. NOESY
correlations observed for H-2/H-3, H-3/H-4, H-4/H-14, H-8/
H-9, H-9/H3-18, H-11/H-18, H-11/H-17, and H-5/H-12
suggested that the H-3, H-8, H-11, H-14, H-17, and H3-18 are
α-oriented and H-5 and H-12 are β-oriented. These assignments
were consistent with the configurations of reported cyclo-
myrsinol diterpenes.25,28,29 Therefore, compound 7 (falcatin G)
was identified as 3β,10β,14β,15β-O-tetraacetyl-5α,8α-O-diben-
zoylcyclomyrsinol.
Table 4. continued
cn.d. not detected.
Journal of Natural Products Article
DOI: 10.1021/acs.jnatprod.6b00260
J. Nat. Prod. XXXX, XXX, XXX−XXX
G
The 1H and 13C NMR spectra of compounds 8 and 9 were
similar to those of falcatin G (7) (Tables 3 and 4). Chemical shift
values for the 20 skeletal carbons were close to those of
3,5,8,10,14,15-O-hexaacylcyclomyrsinol, which implied that
these compounds are polyesters of the same parent alcohol.
For compound 8, five acetoxy and one isobutyryloxy group were
evident from its 13C and 1H NMR spectra. HMBC and NOESY
experiments allowed the determination of the positions of the
acyloxy groups and the relative configuration of 8 (Figure 3).
NOESY correlations demonstrated that H-2, H-3, H-4, H-8,
H-9, H-11, H-14, and H2-17 are α-oriented and H-5, H-12, and
H3-20 are β-oriented. The two differences between 9 and 8 were
that the C-3 isobutyryl and C-8 benzoyl groups in 8 were
replaced by nicotinyl (C-3) and 2-methylbutyryl (C-8) groups in
9. Therefore, compounds 8 and 9 were elucidated as
5α,8β,10β,14β,15β-O-pentaacetyl-3β-O-isobutyrylcyclomyrsi-
nol (8) and 5α,10β,14β,15β-O-tetraacetyl-3β-isobutyryl-8β-O-
(2-methylbutyryl)-3β-O-nicotinylcyclomyrsinol (9) and were
named falcatins H and I, respectively.
Analysis of the 1H and 13C NMR data (Tables 3−6) of
compounds 10−15 revealed all compounds to be based on a
cyclomyrsinane skeleton in a similar manner to 8 and 9, but
having a hydroxy or acyloxy group substituent at C-2, as indicated
by the carbon signals at δC‑2 75.3−85.0 ppm. After defining the
skeleton by 1H−1H COSY and HSQC measurements, HMBC
and NOESY experiments were performed to determine the
locations of the acyl groups and the configurations. For
compound 10, four acetoxy groups at C-5, C-10, C-14, and C-
15, a propionyloxy group at C-3, a 2-methylbutyryloxy group at
C-8, and a hydroxy group at C-2 were elucidated. The only
difference found between 11 and 10 was that the C-3
propionyloxy group in 10 was replaced by an isobutyryloxy
group in 11. Compound 12 differs from 11 by the substitution at
C-2. In the case of 12, a nicotinyloxy group was determined as
being present instead of a hydroxy group in 11, as indicated by
the chemical shift values of C-2 (11: 75.5 ppm, 12: 85.0 ppm).
The only structural difference between 12 and 13 was the
presence of an isobutyryloxy group at C-8 in 13 instead of the 2-
methylbutyryloxy group in 12. Compound 14 differed from 13
also in that a propionyloxy group was determined at C-3 instead
of the isobutyryloxy group found in 13. Compound 15 was a
close analogue of 10, differing only in the substituent at C-2
(hydroxy in 10 and benzoyloxy in 15).
NOE effects observed between H-3/H-4, H-4/H-14, H-4/H3-
16, H-4/H-17a, H-11/H-17b, H-14/H-1α, H-8/H-9, H-9/H-18,
H-18/H-11, and H-5/H-12 in compounds 10−15 revealed that
these compounds have the same configuration, namely, H-3, H-
4, H-9, H-11, H-14, and H2-17 in an α-orientation and H-5 and
H-12 β-oriented. All of the above evidence confirmed the
structures of these compounds as depicted in structural formulas
10−15, and the compounds were named falcatins J−O,
respectively.
The 1H and 13CNMR spectra of compounds 16−18were very
similar (Tables 5−7). From the NMR spectra, a hemiacetal
moiety between C-13 and C-6 could be elucidated with regard to
the oxymethine signals at δH 6.36−6.49 s and δC 97.1 (17-CH).
In the case of all three compounds, six acyl groups were
identified. The 1H NMR and 1H−1H COSY spectra revealed the
structural elements −CH2−CH(CH3)−CHR−CH−CHR− (C-
1−C-2(C-16)−C-3−C-4−C-5) and −CHR−CH2−CH−CH−
CH− (C-7−C-12). The connection of these partial structural
parts was carried out with the use of HMBC correlations.
Diagnostic HMBC cross-peaks between C-17/H-5, C-17/H-7,
C-17/H-12, C-10/H-18, C-10/H-19, C-10/H-12, C-9/H-18, C-
9/H-19, and C-9/H-11 led to the conclusion that these
compounds are premyrsinane derivatives. For compound 16,
four acetoxy, one isobutyryloxy, and one benzoyloxy group were
identified from its 13C and 1H NMR spectra. The locations of the
ester groups were established from the HMBC spectra, with the
acetoxy groups present at C-5, C-14, C-15, and C-17, an
isobutyryloxy group at C-3, and a benzoyloxy group at C-7
(Figure 4).
In the case of 17, in addition to acetyl substituents at C-5, C-
15, and C-17 and the isobutanoyl group at C-3, a nicotinyl group
and a benzoyl group were determined at C-8 and C-14,
respectively. Compound 18 was found to possess a propionyloxy
moiety at C-3 instead of the isobutyryloxy moiety in 17 (Tables
5−7). A careful comparison of the NOESY spectra of 16−18
indicated the same configuration for all three compounds. A
strong NOESY cross-peak between H-4/H-17 proved the α-
orientation of the C-17 methine proton. Moreover, NOE
correlations observed for H-2/H-3, H-3/H-4, H-4/H-14, H-7/
H-8a, H-8a/H-9, H-9/H-11, H-5/H-12, and H-12/H3-20
indicated that H-2, H-3, H-4, H-7, H-9, H-11, and H-14 are α-
oriented, while H-5, H-12, and H3-20 are oriented in a β-manner.
Therefore, compounds 16−18 (falcatins P−R) were elucidated
as 5α,14β,15β,17-O-tetraacetyl-7β-O-benzoyl-3α-O-isobutyryl-
premyrsinol (16), 5α,15β,17-O-triacetyl-14β-benzoyl-3α-O-iso-
butyryl-7β-O-nicotinylpremyrsinol (17), and 5α,15β,17-O-tri-
acetyl-14β-benzoyl-7β-O-nicotinyl-3α-O-propionylpremyrsinol
(18), respectively.
The molecular formula, C41H49NO12, was determined for
compound 19 by the HRESIMS at m/z 748.3373 [M + H]+
(calcd for C41H50NO12, 748.3333). Analysis of its
13C NMR
spectrum (Table 6) revealed the presence of five ester carbonyls
(δC 164.7, 164.9, 170.0, 170.6, and 176.0), which could be
assigned to a nicotinate, a benzoate, two acetate, and one
isobutanoate unit, respectively, based on diagnostic resonances
in the 1H and 13C NMR spectra (Tables 6 and 7). Analysis of the
1H−1H COSY spectrum allowed the identification of the two
spin systems, −CH2−CH(CH3)−CH(R)−CH−CH(R)− (A)
and −CH(R)−CH2−CH−CH−CH− (B), and an isolated O-
substituted methylene (−CH2−OR). HMBC cross-peaks
between C-6 and H-5, H-17a, H-12, H-4, and H-8, between C-
7 and H-5, H-17, and H-8, and between C-10 and H-7, H-12, H-
Figure 3. Selected 1H−1H COSY (bold) and HMBC (C→H)
correlations for 8.
Figure 4. Selected 1H−1H COSY (bold) and HMBC (C→H)
correlations for 16.
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8, H3-18, and H3-19 indicated a premyrsinane skeleton without
the ether functionality between C-17 and C-13. The locations of
the ester groups were established from the HMBC correlations
from δC 176.0 to δH 5.39 (H-3); δC 164.9 to δH 6.42 (H-5); δC
164.7 to δH 5.04 (H-17); and δC 170.0 to δH 5.01 (H-7) and
indicated that isobutanoyl, benzoyl, nicotinyl, and acetyl groups
occurred at C-3, C-5, C-7, and C-17, respectively. The chemical
shift at δC‑15 84.1 indicated clearly a hydroxy group at C-15, and
the last acetyl group was placed at C-13. NOESY experiments led
to the assignment of the configuration of the molecule. Starting
from the α-orientation of H-4, cross-peaks between H-4/H-3, H-
4/H-2, H-4/H-17a, H-4/H3-20, and H-20/H-11 demonstrated
the α-orientation of these protons. The NOE effects observed
between H-5/H-12 and H-5/OH-15 indicated the β-orientation
of H-5, H-12, and OH-15. Consequently, the data obtained
supported the proposed structure of 19 (falcatin S) as 7β,13β-O-
diacetyl-5α-O-benzoyl-15β-hydroxy-3β-O-isobutanoyl-17α-O-
nicotinylpremyrsinol.
Compound 20 was found to be identical in all of its
characteristics, including the 1H NMR and mass spectrometric
data, with euphorprolitherin D, isolated earlier from Euphorbia
prolifera by Zhang et al. in 2004.33
Table 5. 1H NMR Data (δH) of Compounds 13−17 (CDCl3, 500 MHza or 600 MHzb)
position 13a 14a 15a 16b 17a
1α 3.84, d (16.8) 4.22, d (16.9) 4.15, d (16.8) 2.62, m 2.78, dd (16.1, 10.2)
1β 2.84, d (16.7) 2.42, d (16.7) 2.44, d (16.7) 2.39, m 2.67, dd (16.1, 10.0)
2 2.02, m 2.15, m
3 5.61, d (4.4) 5.57, d (5.5) 5.60, d (5.4) 5.02, t (3.6) 5.12, t (3.8)
4 3.21, dd (10.8, 4.4) 3.08, dd (10.8, 5.6) 3.08, dd (10.8, 5.4) 3.02, dd (10.8, 3.6) 3.17, dd (10.7, 3.7)
5 5.92, d (10.8) 5.94, d (10.7) 5.90, d (10.7) 5.77, d (10.8) 5.88, d (10.6)
7 5.31, dd (10.8, 3.1) 5.42, dd (10.6, 3.5)
8 5.27, d (6.6) 5.28, d (6.6) 5.27, d (6.6) 2.02, m; 1.55, m 2.15, m; 1.70 m
9 2.76, m 2.76, m 2.74, m 0.91, m 1.02, m
11 2.52, m 2.47, m 2.46, m 0.74, m 0.89, t (7.0)
12 4.04, d (12.3) 3.97, d (12.2) 3.97, d (12.2) 2.66, m 2.93, d (7.0)
14 5.05, s 5.03, s 5.03, s 4.97, s 5.30, s
16 1.80, s 1.83, s 1.80, s 0.69, d (6.6) 0.76, d (6.8)
17 4.27, d (9.8) 4.26, d (9.8) 4.27, d (9.8) 6.36, s 6.48, s
3.64, d (9.8) 3.62, d (9.9) 3.61, d (9.8)
18 1.66, s 1.64, s 1.64, s 1.13, s 1.28, s
19 2.52, m 2.52, m 2.52, m 1.13, s 1.18, s
20 1.22, s 1.20, s 1.20, s 1.29, s 1.37, s
OProp-3
2 2.21, m, 2.16, dq (16.5, 7.5) 2.17, m
3 1.06, t (7.5) 1.04, t (7.5)
OiBu-3
2 2.40, sept (7.0) 2.43, m 2.49, sept (7.0)
3 1.06, d (6.9) 1.07, d (6.6) 1.11, d (7.0)
4 1.00, d (7.1) 1.05, d (6.6) 1.09, d (7.0)
OAc-5 1.96, s 1.94, s 1.94, s 1.23, s 1.39, s
OAc-10 2.10, s 2.07, s 2.08, s
OAc-14 2.12, s 2.09, s 2.11, s 1.98, s
OAc-15 2.16, s 2.05, s 2.05, s 2.04, s 2.08, s
OAc-17 2.13, s 2.21, s
OiBu-8
2 2.76, m 2.76, m
3 1.26, d (6.8) 1.24, d (7.0)
4 1.23, d (7.2) 1.28, d (6.8)
OMeBu-8
2 2.52, m
3 1.29, d (7.0)
4 0.88, t (7.0)
5 1.23, d (7.1)
ONic
2 9.06, s 9.03, s 9.15, s
4 8.15, d (7.9) 8.18, d (8.0) 8.23, d (7.9)
5 7.36, dd (8.0, 5.0) 7.39, dd (8.1, 4.9) 7.38, dd (7.8, 4.9)
6 8.76, d (4.8) 8.76, d (4.8) 8.78, d (4.7)
OBz
2, 6 7.89, d (8.2) 7.88, d (7.8) 7.95, d (7.3)
3, 5 7.41, t (7.8) 7.34, t (7.6) 7.47, t (7.8)
4 7.53, t (7.4) 7.47, t (7.2) 7.59, t (7.4)
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Table 6. 13C NMR Data (δC) of Compounds 13−19 (CDCl3, 125 MHza or 150 MHzb)
position 13a 14a 15a 16b 17a 18a 19a
1 48.3, CH2 48.8, CH2 49.1, CH2 44.3, CH2 44.3, CH2 44.2, CH2 42.9, CH2
2 84.2, C 84.2, C 83.6, C 35.9, CH 36.2, CH 35.7, CH 37.1, CH
3 78.1, CH 78.4, CH 78.2, CH 76.4, CH 76.6, CH 76.5, CH 77.9, CH
4 47.0, CH 48.6, CH 48.6, CH 53.2, CH 53.4, CH 53.5, CH 50.5, CH
5 68.4, CH 68.9, CH 68.9, CH 67.1, CH 67.4, CH 67.4, CH 69.9, CH
6 62.0, C 62.2, C 62.2, C 55.9, C 56.1, C 55.6, C 48.1, C
7 204.3, C 204.5, C 204.6, C 72.6, CH 72.9, CH 73.1, CH 70.5, CH
8 70.8, CH 70.9, CH 70.9, CH 25.6, CH2 22.9, CH2 22.9, CH2 22.2, CH2
9 29.9, CH 30.0, CH 30.1, CH 23.6, CH 23.4, CH 23.2, CH 23.8, CH
10 77.5, C 77.5, C 77.6, C 19.1, C 19.1, C 19.3, C 18.3, C
11 41.5, CH 41.3, CH 41.3, CH 18.5, CH 18.5, CH 18.6, CH 18.3, CH
12 41.3, CH 41.5, CH 41.5, CH 38.1, CH 37.8, CH 37.9, CH 35.3, CH
13 89.1, C 88.7, C 88.8, C 87.8, C 88.6, C 88.1, C 85.5, C
14 81.5, CH 80.8, CH 80.9, CH 79.7, CH 80.4, CH 80.2, CH 204.0, C
15 88.5, C 89.3, C 89.3, C 89.8, C 89.8, C 89.8, C 84.1, C
16 24.7, CH3 25.6, CH3 25.5, CH3 14.2, CH3 14.6, CH3 14.4, CH3 13.7, CH3
17 67.1, CH2 67.0, CH2 67.0, CH2 97.1, CH 97.3, CH 97.1, CH 63.6, CH2
18 24.4, CH3 24.6, CH3 24.6, CH3 15.8, CH3 16.6, CH3 16.1, CH3 14.8, CH3
19 34.6, CH2 34.6, CH2 34.7, CH2 28.1, CH3 28.3, CH3 28.1, CH3 29.4, CH3
20 22.2, CH3 22.3, CH3 22.2, CH3 24.8, CH3 25.1, CH3 25.0, CH3 24.9, CH3
OProp-3 1 173.0, C 173.0, C 174.0, C
2 27.3, CH2 27.3, CH2 27.6, CH2
3 8.6, CH3 8.5, CH3 9.0, CH3
OiBu-3 1 175.3, C 176.8, C 176.0, C
2 34.0, CH 34.3, CH 34.1, CH
3 18.2, CH3 19.5, CH3 19.2, CH3
4 18.9, CH3 18.6, CH3 18.4, CH3
OAc-5 169.7, C 169.9, C 170.2, C 169.2, C 168.9, C 169.1, C
20.8, CH3 20.8, CH3 20.3, CH3 21.2, CH3 21.5, CH3 21.4, CH3
OAc-7 170.0, C
21.3, CH3
OAc-10 168.7, C 168.7, C 168.8, C
21.5, CH3 21.2, CH3 21.5, CH3
OAc-13 170.6, C
21.3, CH3
OAc-14 170.2, C 170.1, C 170.0, C 170.2, C
21.2, CH3 21.2, CH3 21.3, CH3 21.0, CH3
OAc-15 168.1, C 168.1, C 168.5, C 168.4, C 167.9, C 167.9, C
22.9, CH3 22.3, CH3 20.9, CH3 23.0, CH3 23.0, CH3 22.9, CH3
OAc-17 170.0, C 170.0, C 169.8, C
21.4, CH3 21.6, CH3 21.4, CH3
OiBu 1 175.0, C 174.9, C 176.5, C
2 34.3, CH 34.4, CH 34.5, CH
3 18.4, CH3 20.3, CH3 19.1, CH3
4 20.3, CH3 18.5, CH3 18.8, CH3
OMeBu-8 1 174.9, C
2 34.9, CH
3 18.5, CH2
4 14.1, CH3
5 20.3, CH3
OBz CO 164.7, C 166.1, C 165.3, C 165.5, C 164.9, C
1 129.4, C 129.9, C 130.0, C 129.6, C 129.3, C
2, 6 128.3, CH 128.3, CH 128.6, CH 128.4, CH 127.9, CH
3, 5 133.0, CH 133.1, CH 133.3, CH 133.1, CH 132.7, CH
4 130.5, CH 130.3, CH 129.7, CH 129.4, CH 129.4, CH
ONic 1 163.4, C 163.4, C 164.4, C 164.8, C 164.7, C
2 150.7, CH 150.4, CH 151.3, CH 150.7, CH 150.4, CH
3 126.2, CH 126.6, CH 124.8, CH 128.3, CH 125.1, CH
4 137.0, CH 137.0, CH 137.5, CH 137.2, CH 136.1, CH
5 123.2, CH 123.4, CH 123.3, CH 123.2, CH 123.0, CH
6 153.4, CH 153.4, CH 153.8, CH 153.6, CH 153.0, CH
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Effects of the Investigated Compounds on GIRK and
hERG Potassium Channels. In order to study the possible
potassium channel-blocking capability of the investigated
compounds, screening of the isolated diterpenes with different
skeletons and substitution patterns was performed on a GIRK
channel expressing cell line. Myrsinane, premyrsinane, and
cyclomyrsinane diterpenes substituted with hydroxy, acetyl,
propanoyl, isobutanoyl, 2-methylbutanoyl, n-hexanoyl, benzoyl,
and nicotinyl ester groups were included in the bioassay.
Compounds were screened at two concentrations (1 and 10 μM)
on two to three cells.
Thirteen of the tested compounds (1−3, 8, 9, 12, 14, 15, and
21−24) were found to possess blocking activity (i.e., at least 60%
decrease in the current at 10 μM concentration) on GIRK
channels. All compounds were also tested against the HEK-
hERG (human embryonic kidney cells) cell line, and the
selectivity of their GIRK blocking effect was evaluated with these
experiments. Selectivity studies were performed at three
concentrations (3, 10, and 30 μM) on two or three cells. Five
out of the 13 compounds, falcatins A−C (1−3), falcatin H (8),
and falcatin I (9), which were potent for GIRK channels, exerted
low inhibitory effects on the hERG channel (i.e., a maximum 20%
decrease in the current at 10 μM concentration). Results of the
GIRK screening and the selectivity investigations on hERG are
shown in Table 8.
Compounds with a myrsinane skeleton and with a carbonyl
function at C-7 (1−3) were found to be highly active and
selective inhibitors. In addition, esters of 2-deoxycyclomyrsinane
with an aliphatic ester group at C-8 (8 and 9) were also found to
have selective ion channel activity. These compounds showing
GIRK selectivity were subjected to further investigations. The
dose−response curves of these five compounds on the GIRK
channel were determined in detailed experiments where the
effect of the compounds was tested at four concentrations on at
least five cells. Dose−response curves and IC50 values of these
compounds are shown in Figure 5.
Falcatin A (1) was the most promising agent, with an IC50
value of 2.5± 0.2 μM. The IC50 values of falcatins C (3) and I (9)
were very similar (4.7 ± 0.3 and 4.9 ± 0.2 μM, respectively). In
Table 7. 1H NMR Data (δH) of Compounds 18 and 19
(CDCl3, 500 MHz)
position 18 19
1α 2.81, dd (16.1, 9.6) 3.19, dd (13.6, 7.8)
1β 2.63, dd (16.1, 9.6) 1.65, m
2 2.20, m 1.87, m
3 5.13, t (3.9) 5.39, d (3.5)
4 3.15, dd (10.6, 3.7) 2.44, dd (11.6, 3.5)
5 5.88, d (10.6) 6.42, d (11.6)
7 5.43, dd (10.8, 3.3) 5.01, m
8 2.12, m 2,16, m
1.67, m 1.93, m
9 1.04, m 0.78, m
11 0.88, t (7.7) 0.78, m
12 2.91, d (7.2) 3.61, d (6.2)
14 5.29, s
16 0.76, d (6.8) 0.86, d (6.5)
17a 6.48, s 5.04, d (11.6)
17b 4.56, d (11.6)
18 1.28, s 1.08, s
19 1.18, s 0.98, s
20 1.36, s 1.78, s
OAc-5 1.38, s 1.94, s
OAc-7 2.16, s
OAc-13 2.14, s
OAc-15 2.07, s
OAc-17 2.23, s
OProp-3
2 2.32, m,
2.22, dq (16.5, 7.6)
3 1.07, t (7.6)
OiBu
2 2.49, sept (7.0)
3 1.14, d (7.0)
4 0.96, d (7.0)
OBz
2, 6 7.95, d (7.4) 7.70, d (7.4)
3, 5 7.47, t (7.8) 7.03, t (7.7)
4 7.59, t (7.4) 7.16, t (7.3)
ONic
2 9.15, s 8.84, d (1.3)
4 8.24, d (7.6) 7.61, dt (7.9, 1.3)
5 7.39, dd (7.6, 4.9) 7.00, dd (8.0, 4.7)
6 8.78, d (4.9) 8.54, dd (4.7, 1.3)
15-OH 4.38, s
Table 8. GIRK- and hERG-Inhibitory Effects of Compounds
Isolated from E. falcata
inhibition (%)
GIRK hERG
compound 1 μM 10 μM 3 μM 10 μM 30 μM
1 43 83 9 20 39
2 24 62 5 13 18
3 34 69 0 4 16
4 21 47 11 24 40
5 26 61 13 24 43
6 21 54 20 33 46
8 28 61 8 16 23
9 31 72 4 14 25
10 11 24 8 20 33
11 14 26 12 22 32
12 23 69 20 54 82
13 8 57 8 19 30
14 35 65 11 22 42
15 20 64 16 31 52
17 18 37 48 68 78
19 28 48 14 29 53
20 19 54 12 21 45
21 30 69 19 40 55
22 26 70 14 30 40
23 33 77 14 24 53
24 30 70 0 23 33
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turn, the IC50 value of falcatin B (2) was 6.7 ± 0.3 μM, whereas
that of falcatin H (8) was determined to be 9.7± 0.3 μM. Sample
current curves and time course of the hERG and GIRK current
amplitude during the application of different concentrations of
the most effective compound (falcatin A, 1) are shown in Figure
6.
■ CONCLUSIONS
Nineteen new diterpenes, falcatins A−S (1−19), and the known
compound euphorprolitherin D (20) were isolated from the
whole plants of E. falcata. The new compounds were identified as
tetra-, penta-, hexa-, and heptaesters of the myrsinane,
premyrsinane, and cyclomyrsinane polyols acylated with acetyl,
propanoyl, isobutanoyl, 2-methylbutanoyl, benzoyl, and nic-
otinyl acids. Falcatins D−F (4−6) contain a rare 10,13-epoxy
functionality in their myrsinane structure. Moreover, falcatins L−
O (12−15) are substituted with an ester group, and falcatins J
and K (10 and 11) possess a hydroxy group at C-2. This subclass
of the cyclomyrsinanes has been found only in E. falcata so far.
Biogenetically, naturally occurring myrsinanes and cyclomyrsi-
nanes can be derived from lathyranes through premyrsinanes by
intramolecular cyclization.34 Myrsinol-related diterpenes are
specific to the genus Euphorbia; up to now more than 110
such compounds, including myrsinanes (n = 58), premyrsinanes
(n = 39), and cyclomyrsinanes (n = 19), were isolated from 15
Euphorbia species (E. aellenii, E. aleppica, E. boetica, E.
cheiradenia, E. decipiens, E. falcata, E. kopetdaghi, E. macroclada,
E. microsciadia, E. myrsinites, E. pithyusa subsp. cupanii, E.
prolifera, E. splendida, E. seguieriana, and E. teheranica).22,35−39
Among them, the presence of all three types of myrsinanes has
been reported only from E. prolifera, E. seguieriana, and E. falcata.
The richest source of diterpenes seems to be E. prolifera; to date,
46 such compounds were isolated from the plant, and tigliane-
and lathyrane-type diterpenes were also identified along with
myrsinols.40,41 Moreover, in our study three compounds (4−6)
with a rearranged tetrahydrofuran ring were also isolated from E.
falcata. Previously this type of diterpene was detected in only two
species (E. decipiens and E. cheiradenia).30−32
Figure 5.Dose−response curves of compounds 1−3, 8, and 9 on GIRK
channel inhibitory activity.
Figure 6. Effects of compound 1 on the hERG andGIRK current. (A) Representative hERG current curves recorded during the application of 3, 10, and
30 μM compound 1. The inset shows the applied hERG voltage protocol. (B) Time-course of the hERG current amplitude. (C) Typical GIRK current
curves obtained after the application of 1, 3, 10, and 30 μMcompound 1. The inset shows the applied GIRK voltage protocol. (D) Illustrative time series
showing the GIRK inward current values.
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Myrsinane-related diterpenes are interesting targets of natural
product based drug discovery programs. Recently, their
antiangiogenic, immunomodulatory, immunosuppressive, neu-
roprotective, LPS-induced NO production inhibitory, MDR
reversal, cytotoxic, DNA-damaging, antipyretic-analgesic, prolyl
endopeptidase inhibitory, and urease inhibitory activities have
been reported.25,35−38,42−46 This is the first time that selective
GIRK channel inhibitory activity of natural diterpenes has been
investigated.
In the present study, myrsinane, cyclomyrsinane, and
premyrsinane diterpenes were studied on stable transfected
HEK-hERG (Kv11.1) and HEK-GIRK1/4 (Kir3.1 and Kir3.4)
cells. Blocking activity on the GIRK channel was exerted by 13
compounds (1−3, 8, 9, 12, 14, 15, and 21−24) (61−83% at 10
μM), and, among them, five [falcatins A−C (1−3), falcatin H
(8), and falcatin I (9)] showed low potencies on hERG channels
(4−20% at 10 μM). These compounds with selective activities
on GIRK channels are potential lead compounds for the
treatment of atrial fibrillation. The electrophysiological screening
of structurally diverse diterpenes did not permit a detailed
structure−activity relationship determination, but it was
observed that the most promising compounds, 1−3, are
myrsinanes with a carbonyl function at C-7, an ether bridge
between C-17 and C-13, and no epoxy functionality between C-
10 and C-13. Another group of promising GIRK ion channel
inhibitory compounds was established as 2-deoxycyclomyrsi-
nanes with an aliphatic ester at C-8 (compounds 8 and 9).
■ EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations were
measured in CHCl3 using a PerkinElmer 341 polarimeter. NMR spectra
were recorded in CDCl3 on a Bruker Avance DRX 500 spectrometer at
500 MHz (1H) and 125 MHz (13C) and a Bruker Ultrashield Plus 600
spectrometer at 600 MHz (1H) and 150 MHz (13C), using the signals of
deuterated solvents as references. Two-dimensional NMR data were
acquired and processed with standard Bruker software. Gradient-
enhanced versions of the experiments were used. High-resolution MS
data were recorded on a Waters-Micromass Q-TOF Premier mass
spectrometer equipped with an electrospray source. The resolution was
over 1 ppm. The data were acquired and processed with MassLynx
software. Column chromatography (CC) was carried out on polyamide
(ICN); vacuum liquid chromatography (VLC) on silica gel G (15 μm,
Merck); preparative thin-layer chromatography (preparative TLC) on
silica gel 60 F254 and RP-18 F254 plates (Merck); rotation planar
chromatography (RPC) on silica gel 60 GF254 with a Chromatotron
instrument (Harrison Research); and reversed-phase HPLC on a
LiChrospher RP-18 (5 μm, 250 × 4 mm, Merck) column with a Waters
600 instrument with detection at 254 nm.
Plant Material. Euphorbia falcata was collected in September 2008
in Mosonmagyarov́aŕ (Hungary). The plant material was identified by
one of the authors (G.P.). A voucher specimen (No. 775) has been
deposited at the Herbarium of the Department of Pharmacognosy,
University of Szeged, Szeged, Hungary.
Extraction and Isolation. The fresh plant material (20 kg), which
was stored at −20 °C before processing, was crushed in a blender and
then percolated with MeOH (178 L) at room temperature. The crude
extract was concentrated in vacuo and subjected to solvent−solvent
partitioning with CHCl3 (30 L). On evaporation, an organic-phase
residue of 344 g was obtained, which was chromatographed over a
polyamide column (1100 g) with mixtures of H2O−MeOH (4:1, 3:2,
2:3, and 1:4) as eluents. The fractions obtained with H2O−MeOH (4:1
and 3:2) were combined and subjected to silica gel VLC, using a gradient
system of cyclohexane−EtOAc−MeOH (from 8:2:0 to 0:0:1). The CC
fractions were combined into six fractions according to the TLC
monitoring (fractions 1−6). Fraction 3, eluted with cyclohexane−
EtOAc (7:3), was separated by RPC with cyclohexane−CH2Cl2−
MeOH of increasing polarity (from 8:2:0 to 60:50:3). Subfraction 3/3,
eluted with cyclohexane−CH2Cl2−MeOH (60:30:2), was purified
further by RP-VLC (MeOH−H2O from 1:1 to 85:15) and finally byNP-
TLC with CHCl3−acetone (98:2) to yield falcatin P (16) (1.4 mg).
Fraction 4, obtained with cyclohexane−EtOAc−MeOH (70:30:2), was
further separated by RPC with a cyclohexane−CH2Cl2−MeOH (from
60:30:2 to 50:50:4) gradient system. Subfraction 4/3 eluted with
cyclohexane−CH2Cl2−MeOH (60:40:3) was purified by NP-TLC with
n-hexane−acetone (3:2), then by RP-HPLC withMeOH−H2O (3:1) as
eluent, at a flow rate of 0.5 mL/min, to afford falcatin G (7) (1.1 mg) at
tR 30.3 min. Fraction 5, obtained with cyclohexane−EtOAc−MeOH
(70:30:2), was subjected to RPC, eluted with cyclohexane−CH2Cl2−
MeOH mixtures of increasing polarity (from 70:20:1 to 5:5:1).
Subfraction 5/3, eluted with cyclohexane−CH2Cl2−MeOH (60:30:2),
was further separated on RP-VLC using a MeOH−H2O (from 1:1 to
9:1) gradient system as eluent. Subfraction 5/3/2, eluted with MeOH−
H2O (1:1), was purified further by NP-TLC, with toluene−acetone
(9:1) as developing system, to yield falcatin C (3) (46.3 mg).
Subfraction 5/3/3, eluted with MeOH−H2O (3:2), was separated by
RP-TLC with MeOH−H2O (9:1) to afford falcatin B (2) (3.3 mg).
Subfraction 5/3/4, eluted with MeOH−H2O (7:3), was purified by NP-
TLC with toluene−acetone (4:1) to yield falcatin H (8) (6.3 mg) and
falcatin O (15) (12.3 mg). Subfraction 5/3/5, eluted with MeOH−H2O
(7:3 and 8:2), was separated by NP-TLC with cyclohexane−CH2Cl2−
MeOH (5:15:1), to yield falcatin K (11) (5.5 mg), falcatin F (6) (2.5
mg), and euphorprolitherin D (20) (2.9 mg). The compound observed
at Rf 0.6 was further purified by RP-HPLC, eluted with MeOH−H2O
(7:3) at a flow rate of 1 mL/min, to afford falcatin D (4) (6.7 mg) (tR
11.2 min). Fraction 6, eluted with cyclohexane−EtOAc−MeOH
(20:10:1), was rechromatographed by NP-VLC with cyclohexane−
EtOAc−MeOH (from 6:2:0 to 1:1:1). Subfraction 6/4, eluted with
cyclohexane−EtOAc−MeOH (5:5:1), was further separated by RPC
with cyclohexane−CH2Cl2−MeOH (from 5:15:0 to 15:45:15) as the
eluent system. Subfractions yielded with mixtures of cyclohexane−
CH2Cl2−MeOH (15:45:0.5, 15:45:1.5, and 15:45:3) were finally
purified by RP-TLC with MeOH−H2O (4:1), to yield falcatin A (1)
(24.3 mg), falcatin Q (17) (4.4 mg), falcatin I (9) (6.1 mg), and falcatin
L (12) (3.7 mg). Subfraction 6/5, eluted with cyclohexane−EtOAc−
MeOH (1:1:1), was separated further by RP-VLC with a MeOH−H2O
(from 1:1 to 9:1) gradient system to afford falcatin S (19) (10.0 mg),
falcatin N (14) (4.0 mg), falcatin E (5) (2.5 mg), falcatin J (10) (8.3
mg), and falcatin R (18) (2.7 mg). The subfraction obtained by RP-VLC
with MeOH−H2O (4:1) was purified by RP-HPLC with MeOH−H2O
(7:3), at a flow rate of 1.0 mL/min, to afford falcatin N (14) (11.1 mg)
(tR 15.4 min) and falcatin M (13) (36.5 mg) (tR 19.2 min).
Falcatin A (1): amorphous solid; [α]25D −8 (c 0.2, CHCl3); 1H and
13C NMR data, see Tables 1 and 2; HRESIMSm/z 677.2594 [M +Na]+
(calcd for C35H42O12Na, 677.2574), 672.3051 [M + NH4]
+ (calcd for
C35H46NO12, 672.3020).
Falcatin B (2): amorphous solid; [α]28D +22 (c 0.1, CHCl3);
1H and
13C NMR data, see Tables 1 and 2; HRESIMSm/z 629.2600 [M +Na]+
(calcd for C31H42O12Na, 629.2574), 624.3051 [M + NH4]
+ (calcd for
C31H46NO12, 624.3020).
Falcatin C (3): amorphous solid; [α]28D +13 (c 0.1, CHCl3);
1H and
13C NMR data, see Tables 1 and 2; HRESIMSm/z 643.2756 [M +Na]+
(calcd for C32H44O12Na, 643.2731), 638.3211 [M + NH4]
+ (calcd for
C32H48NO12, 638.3177).
Falcatin D (4): amorphous solid; [α]25D +16 (c 0.1, CHCl3);
1H and
13C NMR data, see Tables 1 and 2; HRESIMS m/z 697.3256 [M + H]+
(calcd for C38H49O12, 697.3224), 719.3070 [M + Na]
+ (calcd for
C38H48O12Na, 719.3044).
Falcatin E (5): amorphous solid; [α]25D +14 (c 0.2, CHCl3);
1H and
13C NMR data, see Tables 1 and 2; HRESIMS m/z 683.3092 [M + H]+
(calcd for C37H47O12, 683.3068), 705.2907 [M + Na]
+ (calcd for
C37H46O12Na, 705.2887).
Falcatin F (6): amorphous solid; [α]25D +2 (c 0.1, CHCl3);
1H and
13C NMR data, see Tables 1 and 2; HRESIMSm/z 691.3125 [M +Na]+
(calcd for C37H48O11Na, 691.3094), 686.3574 [M + NH4]
+ (calcd for
C37H52NO11, 686.3540).
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Falcatin G (7): amorphous solid; [α]28D +20 (c 0.04, CHCl3);
1H and
13C NMR data, see Tables 3 and 4; HRESIMS m/z 775.2986 [M + H]+
(calcd for C42H47O14, 775.2966).
Falcatin H (8): amorphous solid; [α]28D +57 (c 0.1, CHCl3);
1H and
13C NMR data, see Tables 3 and 4; HRESIMSm/z 701.2815 [M +Na]+
(calcd for C34H46O14Na, 701.2785), 696.3270 [M + NH4]
+ (calcd for
C34H50NO14, 696.3231).
Falcatin I (9): amorphous solid; [α]25D +63 (c 0.1, CHCl3);
1H and
13C NMR data, see Tables 3 and 4; HRESIMS m/z 756.3264 [M + H]+
(calcd for C39H50NO14, 756.3231), 778.3083 [M + Na]
+ (calcd for
C39H49NO14Na, 778.3051).
Falcatin J (10): amorphous solid; [α]25D +108 (c 0.1, CHCl3);
1H and
13C NMR data, see Tables 3 and 4; HRESIMSm/z 745.3078 [M +Na]+
(calcd for C36H50O15, 745.3047).
Falcatin K (11): amorphous solid; [α]25D +77 (c 0.1, CHCl3);
1H and
13C NMR data, see Tables 3 and 4; HRESIMSm/z 759.3240 [M +Na]+
(calcd for C37H52O15Na, 759.3204).
Falcatin L (12): amorphous solid; [α]25D +30 (c 0.1, CHCl3);
1H and
13C NMR data, see Tables 3 and 4; HRESIMS m/z 842.3640 [M + H]+
(calcd for C43H56NO16, 842.3599), 864.3463 [M + Na]
+ (calcd for
C43H55NO16Na, 864.3419).
Falcatin M (13): white powder; [α]28D +84 (c 0.2, CHCl3);
1H and
13C NMR data, see Tables 5 and 6; HRESIMS m/z 828.3479 [M + H]+
(calcd for C42H54NO16, 828.3443), 850.3292 [M + Na]
+ (calcd for
C42H53NO16Na, 850.3262).
Falcatin N (14): amorphous solid; [α]25D +53 (c 0.1, CHCl3);
1H and
13C NMR data, see Tables 5 and 6; HRESIMS m/z 814.3333 [M + H]+
(calcd for C41H52NO16, 814.3286), 836.3145 [M + Na]
+ (calcd for
C41H51NO16Na, 836.3106).
Falcatin O (15): amorphous solid; [α]25D +65 (c 0.1, CHCl3);
1H and
13C NMR data, see Tables 5 and 6; HRESIMS m/z 827.3479 [M + H]+
(calcd for C43H55O16, 827.3490).
Falcatin P (16): amorphous solid; [α]28D −13 (c 0.04, CHCl3); 1H
and 13C NMR data, see Tables 5 and 6; HRESIMS m/z 741.3501 [M +
H]+ (calcd for C40H53O13, 741.3486).
Falcatin Q (17): amorphous solid; [α]25D−16 (c 0.1, CHCl3); 1H and
13C NMR data, see Table 5 and 6; HRESIMS m/z 790.3474 [M + H]+
(calcd for C43H52NO13, 790.3439), 812.3292 [M + Na]
+ (calcd for
C43H51NO13Na, 812.3258).
Falcatin R (18): amorphous solid; [α]25D−18 (c 0.2, CHCl3); 1H and
13C NMR data, see Tables 6 and 7; HRESIMS m/z 776.3316 [M + H]+
(calcd for C42H50NO13, 776.3282), 798.3129 [M + Na]
+ (calcd for
C42H49NO13Na, 798.3102).
Falcatin S (19): amorphous solid; [α]25D−23 (c 0.1, CHCl3); 1H and
13C NMR data, see Tables 6 and 7; HRESIMS m/z 748.3373 [M + H]+
(calcd for C41H50NO12, 748.3333), 770.3186 [M + Na]
+ (calcd for
C41H49NO12Na, 770.3152).
Euphorprolitherin D (20): amorphous solid; [α]25D +74 (c 0.1,
CHCl3);
1H and 13C NMR data identical with published data.33
Electrophysiological Investigations. GIRK and hERG ion
currents were measured using planar patch-clamp technology with a
four-channel medium throughput fully automated patch-clamp system
(Patchliner, Nanion Technologies GmbH, Munich, Germany).47
Whole-cell configuration was applied in all experiments. The pipetting
protocols were controlled by PatchControlHT 1.07.50 software
(Nanion Technologies GmbH). Current recordings and online analysis
were performed with an EPC-10 Quadro patch-clamp amplifier (HEKA
Elektronik Dr. Schulze GmbH) using the PatchMaster 2.43 software
(HEKA Elektronik Dr. Schulze GmbH, Lambrecht/Pfalz, Germany).
Automated patch-clamp experiments were carried out at room
temperature with a suspension of stable transfected cell lines.
Suspensions of cells for measurements were derived from running cell
cultures. Cells were maintained in an incubator at 37 °C, in 5% CO2.
Before experiments, cells were washed twice with PBS (Life
Technologies Corporation, Carlsbad, CA, USA) and then detached
with trypsin-EDTA (PAA Laboratories GmbH, Pasching, Austria) for
1−3 min. Trypsin was blocked with serum containing complete culture
medium. The cell suspension was next centrifuged (2 min, 100g),
resuspended in serum-free basemedium at a final density of 1× 106−5×
106 cells/mL, and kept in the cell hotel of the Patchliner system. Cells
were recovered after 15−30 min and remained suitable for automated
patch-clamp recordings for up to 4 h.
Stocks of extra- and intracellular solutions were made for automated
patch-clamp recordings. Chemicals were purchased from Sigma-Aldrich
Corporation (St. Louis, MO, USA). All solutions were sterile filtered.
Aliquots were stored at −20 °C and warmed to room temperature
before use.
For each diterpene isolated from E. falcata, a stock solution of test
compound (10 mM) was prepared. The solubilizing agent was dimethyl
sulfoxide (DMSO, Sigma-Aldrich Corporation). Aliquots were stored at
−20 °C. Before experiments, stock solutions were further diluted with
high K+ external solution (GIRK assay) or external solution (hERG
assay) to give appropriate concentrations for the measurements. The
final DMSO concentrations in the tested samples were 0.3% or less.
GIRK Channel Inhibitory Assay. Experiments were carried out on
HEK-293 (human embryonic kidney) cells stably expressing GIRK1/4
(Kir3.1/3.4) K+ channels.48 This cell line originated from UCL Business
PLC (London, UK). Cells were maintained inMEM (PAA Laboratories
GmbH) medium supplemented with 10% FBS (fetal bovine serum)
(PAA Laboratories GmbH) and 182 μg/mL zeocin (Life Technologies
Corporation).
The following solutions were used during patch-clamp recordings
(compositions in mM): external solution: NaCl 140, KCl 4, glucose-
monohydrate 5, MgCl2 1, CaCl2 3, and HEPES 10 (pH 7.4, NaOH);
high K+ external solution: NaCl 135, KCl 25, MgCl2 1, CaCl2 3, and
HEPES 10 (pH 7.4, NaOH); K+-free external solution: NaCl 160,
MgCl2 1, CaCl2 3, andHEPES 10 (pH 7.4, NaOH); internal solution: K-
gluconate 40, NaCl 20, KF 60, EGTA 20, and HEPES 10 (pH 7.2,
KOH), supplemented with 0.9 mM GTPγS (guanosine 5′-O-(γ-
thio)triphosphate) before the experiments to induce channel activation.
The voltage protocol for the GIRK ion channel assay (see inset in
panel C, Figure 6) started with a depolarizing voltage step to 60 mV for
100 ms before a 500 ms long hyperpolarizing ramp to −140 mV was
applied. Then, the membrane potential remained at −140 mV for 100
ms before returning to the holding potential of −40 mV. The inward
currents were calculated from the −140 mV segment. The pulse
frequency was approximately 0.1 Hz.
At the beginning of the recordings, the normal external solution (4
mM K+) was replaced with a high-K+ external solution in order to
increase the current amplitude. After 3 min of a control period, the test
compounds were added to the cells in increasing concentrations (1 and
10 μM in the case of screening; 1, 3, 10, and 30 μM for each IC50 assay),
for approximately 2 min. Propafenone (1 μM, Sigma-Aldrich
Corporation) was used as a reference compound, and then potassium-
free external solution was applied. The data were corrected with the
current values measured in the potassium-free external solution, which
served as the baseline.
hERG Channel Inhibitory Assay. hERG measurements were
performed on HEK-293 cells stably transfected with cDNA encoding
the hERG (Kv11.1) K+ channel.49 The cell line was purchased from Cell
Culture Service (Hamburg, Germany). Cells were maintained in IMDM
(Iscove’s modified Dulbecco’s medium) (PAA Laboratories GmbH)
medium supplemented with 10% FBS (PAA Laboratories GmbH), 2
mM L-glutamine (Life Technologies Corporation), 1 mM Na-pyruvate
(PAA Laboratories GmbH), and 500 μg/mL G418 (PAA Laboratories
GmbH).
The following solutions were used during patch-clamp experiments
(compositions in mM): external solution: NaCl 140, KCl 4, glucose-
monohydrate 5, MgCl2 1, CaCl2 3, and HEPES 10 (pH 7.4, NaOH);
internal solution: KCl 50, NaCl 10, KF 60, EGTA 20, and HEPES 10
(pH 7.2, KOH).
The voltage protocol for the hERG ion channel (see inset in panel A,
Figure 6) started with a short (100 ms) −40 mV voltage step, as a
reference. A 20 mV depolarizing step was applied for 3 s, and then the
test potential was −40 mV for 1 s to evoke an outward tail current. The
holding potential was−80 mV, and the pulse frequency was 0.1 Hz. The
peak tail current was corrected with the leak current defined during the
first period to −40 mV.
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The recording started in the external solution. After this control
period, increasing concentrations of each test compound (3, 10, and 30
μM, respectively) were applied, each for approximately 3min. Following
test compound administration, 10 μM amitriptyline was applied as a
reference inhibitor followed by a wash-out step.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.jnat-
prod.6b00260.
Representative 1D and 2D NMR spectra of the diterpenes
isolated from Euphorbia falcata illustrating myrsinane-,
cyclomyrsinane-, and premyrsinane-type polyesters
(PDF)
■ AUTHOR INFORMATION
Corresponding Author
*Tel: +36-62-546453. Fax: +36-62-547404. E-mail: hohmann@
pharm.u-szeged.hu.
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
Financial support from the Hungarian Scientific Research Fund
(OTKA K109846) is gratefully acknowledged. A.V. acknowl-
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